Bone metastasis in prostate cancer: emerging therapeutic strategies
Top Cited Papers
- 10 May 2011
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Clinical Oncology
- Vol. 8 (6), 357-368
- https://doi.org/10.1038/nrclinonc.2011.67
Abstract
Metastatic bone disease (MBD) in advanced-stage cancer increases the risk of intractable bone pain, pathological skeletal fracture, spinal-cord compression and decreased survival. The disease manifestation course during MBD is largely driven by homotypic and heterotypic cellular interactions between invading tumor cells, osteoblasts and osteoclasts. The outcome is a sustained vicious cycle of bone matrix remodeling. Osteoclast-mediated bone degradation and subsequent bone loss are the hallmarks of secondary bone metastases from most solid tumors. An additional complication in prostate cancer is the predominance of osteosclerotic lesions typified by inappropriate bone production. Successful therapeutic strategies for the treatment of osteolytic MBD include the administration of intravenous bisphosphonates or subcutaneous inhibitors of receptor activator of nuclear factor κB ligand (RANKL). Inhibitors of SRC and cABL kinases and cathepsin K are under clinical investigation as potential anti-osteolytics. In contrast to the rapid progress being made in the development of anti-osteolytic therapies, the treatment of osteosclerotic MBD remains restricted to palliative radiotherapy for symptomatic solitary lesions and systemic taxane-based chemotherapy for widespread multiple lesions. This Review discusses the complex pathology of bone lesions in metastatic castration-resistant prostate cancer and focuses on new therapeutic strategies and targets that are emerging in preclinical studies.Keywords
This publication has 125 references indexed in Scilit:
- Novel actions of bisphosphonates in bone: Preservation of osteoblast and osteocyte viabilityBone, 2011
- Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblastsOncogene, 2010
- A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFβ signaling for breast cancer therapyCancer Gene Therapy, 2009
- Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trialsThe Lancet Oncology, 2009
- Denosumab Treatment of Prostate Cancer With Bone Metastases and Increased Urine N-Telopeptide Levels After Therapy With Intravenous Bisphosphonates: Results of a Randomized Phase II TrialJournal of Urology, 2009
- Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysisBritish Journal of Cancer, 2009
- TGF-β1–induced migration of bone mesenchymal stem cells couples bone resorption with formationNature Medicine, 2009
- Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate CancerJournal of Clinical Oncology, 2009
- Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastasesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2007
- Osteoclast differentiation and activationNature, 2003